International report finds access to breast cancer drugs across the UK is falling behind other countries - including Germany, France and Canada - with thousands missing out on life-extending treatments.
The research by Breast Cancer Now and Prostate Cancer UK showed this is likely in part because the UK's appraisal systems lack the opportunity to negotiate on the price of drugs. The 'International Comparisons of Health Technology Assessment' report - published today - reviewed the drug systems and the availability of breast and prostate cancer treatments in England, Scotland and Wales compared to five similar countries: Germany, France, Australia, Canada and Sweden. It shows for example that Kadcyla - a drug that can offer women living with incurable secondary breast cancer an extra ...
To continue reading this article...
Join COVER for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, key trend analysis and industry insights.
- Stay on top of the latest developments around health and wellbeing, diversity and inclusion and the cost of living crisis.
- Receive breaking news stories straight to your inbox in the daily newsletter.
- Members only access to monthly programme 'The COVER Review'
- Be the first to hear about our CPD accredited events and awards programmes.
